HC Wainwright Predicts Acelyrin's Q1 Earnings (NASDAQ:SLRN)

Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Acelyrin in a research note issued on Tuesday, January 7th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.44) per share for the quarter. HC Wainwright has a "Neutral" rating and a $6.00 price objective on the stock. The consensus estimate for Acelyrin's current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Acelyrin's Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.15) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at ($1.04) EPS.

Other analysts have also recently issued reports about the company. Citigroup dropped their target price on Acelyrin from $6.00 to $3.00 and set a "neutral" rating for the company in a report on Tuesday. Wells Fargo & Company dropped their price objective on shares of Acelyrin from $15.00 to $13.00 and set an "overweight" rating for the company in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $9.60.

Acelyrin Price Performance

Shares of NASDAQ:SLRN traded down $0.06 during midday trading on Thursday, hitting $2.14. The company had a trading volume of 4,439,974 shares, compared to its average volume of 4,007,035. Acelyrin has a twelve month low of $1.91 and a twelve month high of $8.89. The stock has a market cap of $214.70 million, a price-to-earnings ratio of -0.87 and a beta of 1.94. The business's 50-day simple moving average is $4.16 and its 200-day simple moving average is $4.84.

Institutional Trading of Acelyrin

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in shares of Acelyrin during the third quarter valued at about $50,000. HighTower Advisors LLC acquired a new stake in Acelyrin in the 3rd quarter valued at approximately $50,000. Principal Financial Group Inc. acquired a new stake in Acelyrin in the 2nd quarter valued at approximately $49,000. Intech Investment Management LLC purchased a new stake in Acelyrin in the third quarter valued at approximately $77,000. Finally, US Bancorp DE lifted its stake in Acelyrin by 77.1% during the third quarter. US Bancorp DE now owns 16,854 shares of the company's stock worth $83,000 after purchasing an additional 7,336 shares in the last quarter. 87.31% of the stock is currently owned by hedge funds and other institutional investors.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.